Brief: Hyloris Pharmaceuticals Expands Pipeline With Product Candidate For Hypophosphatemia

Hyloris Pharmaceuticals SA

20/01/2023 06:06

Jan 20 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * REG-HYLORIS PHARMACEUTICALS EXPANDS ITS PIPELINE WITH A
PRODUCT
CANDIDATE FOR A MINERAL DEFICIENCY IN THE BLOOD
(HYPOPHOSPHATEMIA)
    * TARGETS REGULATORY APPROVAL IN EUROPE, WITH POSSIBLE
FURTHER
EXTENSIONS
    * EXPECTED COSTS FOR HYLORIS STAY WELL BELOW OUR REQUIRED
AVERAGE
INVESTMENT OF LESS THAN EUR 7 MILLION PER PRODUCT CANDIDATE
    * THIS BRINGS US ONE STEP CLOSER TO A TOTAL PIPELINE OF 30
ASSETS,
A GOAL WE AIM TO ACHIEVE BEFORE 2025.
    * INTENDS TO CONDUCT STREAMLINED DEVELOPMENT PROGRAM TO
ACHIEVE
MARKET ACCESS IN EUROPE, TARGETING REGULATORY APPROVAL IN
EUROPEAN COUNTRIES AS FROM 2026

Source text for Eikon:  ID:nGNER9Ycr 
Further company coverage:  HYL.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))